v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Costs and expenses:    
Research and development $ 10,513,579 $ 2,751,279
Selling, general and administrative 5,249,291 2,031,081
Change in fair value contingent consideration (1,164,864) 0
Total costs and expenses 14,598,006 4,782,360
Loss from operations (14,598,006) (4,782,360)
Interest income 919,271 132,725
Net loss (13,678,735) (4,649,635)
Other comprehensive income (loss), net of tax    
Unrealized gain (loss) on marketable securities 36,281 (2,677)
Comprehensive loss $ (13,642,454) $ (4,652,312)
Net loss per share - basic $ (0.15) $ (0.73)
Net loss per share - diluted $ (0.15) $ (0.73)
Weighted-average number of shares basic 89,537,171 6,340,697
Weighted-average number of shares diluted 89,537,171 6,340,697